Navigation Links
Faruqi & Faruqi, LLP Announces Investigation of GenVec, Inc.
Date:2/6/2012

NEW YORK, Feb. 6, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at GenVec, Inc. ("GenVec" or the "Company") (Nasdaq: GNVC).   

(Logo:  http://photos.prnewswire.com/prnh/20120119/MM38856LOGO)

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that GenVec's much publicized product, TNFerade, designed for the treatment of certain cancers and infectious diseases (HIV, malaria, influenza, foot-and-mouth disease, respiratory syncytial virus, and HSV-2), was not effective.

On March 29, 2010, GenVec announced that it was discontinuing its Phase III clinical trial of TNFerade in patients with locally advanced pancreatic cancer. On this news, the Company's stock price declined by $20.10 per share – from $28.10 per share on March 29, 2010 to a close of $8.00 per share on March 30, 2010 – a decline of more than 71.5% on unusually high volume.

Request more information now by clicking here:  www.faruqilaw.com/GNVC

Take Action

If you purchased GenVec securities between March 12, 2009 and March 30, 2010 and would like to discuss your legal rights, visit www.faruqilaw.com/GNVC.  You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding GenVec's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential matter.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Francis McConville, Esq.
fmcconville@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330


'/>"/>
SOURCE Faruqi & Faruqi, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Smith & Nephew Reaches Settlement With US Government
2. In Honor of American Heart Month, Joy Behar & Daughter Eve Call on Women to Take the ProHeart Pledge on Facebook
3. Aria Announces Publication of Independent Study in the American Journal of Obstetrics & Gynecology Using Arias Technology
4. Tris Pharma Announces Appointment of Dr. Mahdi Fawzi as Top R&D Executive
5. Validation & Compliance Institute Provides Affordable Online FDA Training
6. Radient Pharmaceuticals Introduces its 2012 Sales, Advertising & Outreach Plan Presentation
7. Johnson & Johnson Reports 2011 Fourth-Quarter and Full-Year Results:
8. Niagara Thermal Products LLC Announces the Acquisition of J. Kittredge & Sons, Inc.
9. MD&M West 2012 to Feature Twenty Collocated Conferences
10. Berkery Noyes Releases 2011 Pharma & Healthcare Information and Technology Industry Mergers & Acquisitions Report
11. W. L. Gore & Associates Named a Top U.S. Workplace
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 23, 2016 Global Paclitaxel Market ... profiles 12 companies and the Paclitaxel analysis in this ... the industry and its players. This is ... nature, details the current state of the industry while ... classifications, applications and industry chain structure. The Paclitaxel market ...
(Date:5/23/2016)... ALBANY, New York , May 23, 2016 /PRNewswire/ ... new market report titled, " Exocrine Pancreatic Insufficiency Market ... Forecast 2013 - 2023 ." According to the report, ... at a CAGR of 8.3% from 2015 to 2023 ... pancreatic insufficiency (EPI) is a condition characterized by the ...
(Date:5/23/2016)... Clarifying Vision - Prospects and Developments in ... What can be expected from the Ophthalmic ... the fastest rates? This visiongain report shows ... and prospects. ,Our 190-page report provides ... areas in the industry and the future market prospects. ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... ... Sterling Global Products is launching a Kickstarter campaign focused on “PAW Patrol ... campaign kick-off video is located via this link https://youtu.be/WsO4qz2odco . The campaign will ... raise $1,000 per day for a total of $25,000. The funds will be used ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... of its services to provide one resource, from start to finish, for Life ... Life Safety Statement of Condition surveys requested by the Joint Commission, and fire ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... organization, is pleased to welcome new Partner Firm Austin & Co., Inc. ... approach to insurance, employee benefits, HR consulting, benefits technology, and beyond. As ...
(Date:5/24/2016)... ... May 24, 2016 , ... How to Write Error Free Procedures, ... http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major cause of quality ... ever be totally eliminated, many human performance problems can be prevented. , How to ...
(Date:5/24/2016)... ... (PRWEB) May 24, 2016 -- Grow Healthy ... Advisory Board. Joining the Grow Healthy Advisory Board team are ... embody the mission of our organization and bring talent, expertise and ... as we continue to expand our footprint as the leader in ...
Breaking Medicine News(10 mins):